Loading
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Regular session
$0.95
+$0.08 · +9.20%
Regular session · ET · Market data may be delayed.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Day range
Current $0.95
52-week range
Current $0.95
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
54
Mixed
Risk
79
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Day range
Current $0.95
52-week range
Current $0.95
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 160K USD | 160K USD | 160K USD | 98K USD |
| Gross profit | — | −160K USD | −160K USD | −160K USD | −98K USD |
| Research and development | 2.14M USD | 414K USD | 82K USD | 87K USD | 183K USD |
| Selling, general, and administrative | 3.44M USD | 1.77M USD | 1.47M USD | 324K USD | 1.66M USD |
| Operating expenses | 5.57M USD | 2.18M USD | 1.55M USD | 411K USD | 1.85M USD |
| Interest income | 125K USD | — | — | — | — |
| Interest expense | — | 859K USD | 98K USD | 479K USD | 202K USD |
| Depreciation and amortization | 160K USD | 160K USD | 160K USD | 160K USD | 98K USD |
| Operating income | −5.57M USD | −2.34M USD | −1.71M USD | −571K USD | −1.94M USD |
| Net income | −5.45M USD | −2.6M USD | −1.81M USD | −1.05M USD | −2.15M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 1, 2026 | 1:7 | — | — |
Effective Sep 1, 2026
1:7
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
